Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression.

Kong, Ben L; Stommel, Jayne M; Keck, Jamie M; Kilburn, David; Streblow, Aaron; Egger, Julian; Creason, Allison L; Suciu, Christopher G; Guimaraes, Alexander R; Corless, Christopher L; Mills, Gordon B; Pejovic, Tanja B

Kong, Ben L; Stommel, Jayne M; Keck, Jamie M; Kilburn, David; Streblow, Aaron; Egger, Julian; Creason, Allison L; Suciu, Christopher G; Guimaraes, Alexander R; Corless, Christopher L; Mills, Gordon B; Pejovic, Tanja B.

Afiliação

Kong BL; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Stommel JM; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Keck JM; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Kilburn D; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Streblow A; Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR.
Egger J; Oregon Health & Science University School of Medicine, Portland, OR.
Creason AL; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Suciu CG; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Guimaraes AR; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Corless CL; Department of Diagnostic Radiology, Oregon Health & Science University, Portland, OR.
Mills GB; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Pejovic TB; Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR.

JCO Precis Oncol ; 8: e2300686, 2024 Jun.

Article em En | MEDLINE | ID: mdl-38905574

ABSTRACT

ABSTRACT

Case report of a HER2-expressed ovarian clear cell carcinoma with exceptional response to trastuzumab deruxtecan.

Assuntos

Recidiva Local de Neoplasia; Neoplasias Ovarianas; Receptor ErbB-2; Trastuzumab; Humanos; Feminino; Trastuzumab/uso terapêutico; Neoplasias Ovarianas/tratamento farmacológico; Neoplasias Ovarianas/genética; Receptor ErbB-2/genética; Recidiva Local de Neoplasia/tratamento farmacológico; Adenocarcinoma de Células Claras/tratamento farmacológico; Adenocarcinoma de Células Claras/patologia; Adenocarcinoma de Células Claras/genética; Antineoplásicos Imunológicos/uso terapêutico; Camptotecina/análogos & derivados; Camptotecina/uso terapêutico; Pessoa de Meia-Idade; Imunoconjugados/uso terapêutico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Receptor ErbB-2 / Trastuzumab / Recidiva Local de Neoplasia Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google